Orla Gray

The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry.

Increasing age at disability milestones among MS patients in the MSBase Registry.

Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon Beta 1a dosages for multiple sclerosis.

Predictors and dynamics of postpartum relapses in women with multiple sclerosis.

Sex as a determinant of relapse incidence and progressive course of multiple sclerosis.

Risk of relapse phenotype recurrence in multiple sclerosis.

Seasonal variation of relapse rate in multiple sclerosis is latitude dependent.

Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis.

Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS.

Symptomatic therapy in multiple sclerosis: Big pharma should do more - NO.

The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.

Defining reliable disability outcomes in multiple sclerosis.